table1_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

“…Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

image2_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.jpeg by Jordi Rodon (201558)

“…Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

table2_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

“…Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

image1_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.jpeg by Jordi Rodon (201558)

“…Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

table4_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

“…Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”

The incidence, death and DALYs in individuals aged 0 to 19 years in 204 countries and territories in 2021. by Xue Li (285380)

ASDR of Tuberculosis for the 21 Global Burden of Disease regions by SDI, 1990-2021. by Xue Li (285380)

Temporal trends of tuberculosis ASIR by Xue Li (285380)

Age standardized incidence rates of Tuberculosis for the 21 Global Burden of Disease regions by SDI, 1990-2021. by Xue Li (285380)

ASMR of Tuberculosis for the 21 Global Burden of Disease regions by SDI, 1990-2021. by Xue Li (285380)

Incidence, death and DALYs of TB, by age and sex in 2021. by Xue Li (285380)

Fig 1 - by Denise Wajnsztajn (3366902)

Differentially expressed genes measured in bulk RNA-seq. by Jillian A. Bristol (5566289)

Comparable IC examples from spatial down sampling experiment. by Sydney C. Weiser (15383531)

Gene expression analyses of Cluster 6. by Jillian A. Bristol (5566289)

Both T1 and T2 LCLs can be separated into 11 separate clusters in scRNA-seq analysis. by Jillian A. Bristol (5566289)

DataSheet_5_Agouti overexpression in a transgenic model regulates integrity, permeability and electrogenic amino acid transport in zebrafish intestine.pdf by Esther Leal (415661)

Fig 4 - by Denise Wajnsztajn (3366902)

Image_2_The Recombinant Eg.P29-Mediated miR-126a-5p Promotes the Differentiation of Mouse Naive CD4+ T Cells via DLK1-Mediated Notch1 Signal Pathway.tif by Xiancai Du (10970190)

“…One week after P29 immunization of mice, we found that miR-126a-5p was significantly increased and DLK1 expression was decreased, while Notch1 pathway activation was enhanced and Th1 response was significantly stronger. …”

Image_1_The Recombinant Eg.P29-Mediated miR-126a-5p Promotes the Differentiation of Mouse Naive CD4+ T Cells via DLK1-Mediated Notch1 Signal Pathway.tif by Xiancai Du (10970190)

“…One week after P29 immunization of mice, we found that miR-126a-5p was significantly increased and DLK1 expression was decreased, while Notch1 pathway activation was enhanced and Th1 response was significantly stronger. …”